{"schema_version":"secwatch.filing_event.v1","accession":"0001274737-25-000003","form_type":"8-K","ticker":"XGN","cik":"0001274737","company_name":"EXAGEN INC.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.166102+00:00","generated_at":"2026-05-28T02:52:59.732960+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Exagen gets conditional NY approval for new SLE/RA biomarkers; reports record 2024 revenue of $55.3-55.8M","bullets":["Conditional NY State approval for new SLE and RA biomarker assays on AVISE CTD; commercial launch January 2025.","Preliminary FY2024 revenue $55.3-$55.8M (record), net loss $14.8-$15.8M, adjusted EBITDA ($9.8)-($10.8M).","AVISE CTD trailing 12-mo ASP $408-$412, up $72-$76 vs Q4 2023; net neutral cash usage in Q4.","Cash, cash equivalents and restricted cash $22.2M as of Dec 31, 2024.","CEO says profitability 'firmly within reach' with strong growth catalysts entering 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001274737-25-000003","json":"https://secwatch.observer/filing/0001274737-25-000003.json","markdown":"https://secwatch.observer/filing/0001274737-25-000003.md","text":"https://secwatch.observer/filing/0001274737-25-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1274737/000127473725000003/0001274737-25-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1274737/000127473725000003/exdx-20250112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:52:59.732960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}